NC
ATNM icon

nVerses Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

nVerses Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,200
Closed -$16.3K – 1000
2024
Q2 		$16.3K Buy
+2,200
New +$18.1K 0.01% 834

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

nVerses Capital's ATNM Position: Q3 2024 in Review

nVerses Capital sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 2,200 shares — an estimated $16.3K sold.

nVerses Capital first reported a position in ATNM in Q2 2024 and held it in 1 quarter. The position peaked at $16.3K in Q2 2024. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

  • nVerses Capital reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 2,200 Actinium Pharmaceuticals shares in Q3 2024, an estimated $16.3K.
  • nVerses Capital first reported a position in Actinium Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Actinium Pharmaceuticals position peaked at $16.3K in Q2 2024.
  • 72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.